A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer.

The aim of this phase I study was to determine the maximum tolerated dose of a 3-h infusion of paclitaxel, combined with carboplatin at a fixed AUC of 7 mg ml-1 min every 4 weeks for up to six cycles and to evaluate any possible pharmacokinetic interaction. Twelve chemonaive patients with ovarian ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Siddiqui, N., Boddy, A. V., Thomas, H. D., Bailey, N. P., Robson, L., Lind, M. J., Calvert, A. H.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group|1 1997
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063279/
https://www.ncbi.nlm.nih.gov/pubmed/9010040

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063279/
https://www.ncbi.nlm.nih.gov/pubmed/9010040

Ejemplares similares